|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| C07K 16/30 | |||
| A61P 35/00 | |||
| A61K 39/395 |
| (11) | Patento numeris | 3521312 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19163475.7 |
| Europos patento paraiškos padavimo data | 2014-02-20 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-08-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-04-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201361766798 P | 2013-02-20 | US | |
| 201361831809 P | 2013-06-06 | US |
| (72) |
BONNAFOUS, Cécile, FR
SICARD, Hélčne, FR
BUFFET, Renaud, FR
|
| (73) |
Innate Pharma,
117 Avenue de Luminy, 13009 Marseille,
FR
|
| (54) | A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA |
| A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA |